NASDAQ:MNPR | Free Cash Flow | Monopar Therapeutics

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2016-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$3.47M
2025-12-31-$3.37M
2025-03-31-$5.66M
2024-12-31-$2M
2024-03-31-$1.66M
2023-12-31-$1.55M
2023-03-31-$2.27M
2022-12-31-$1.3M
2022-03-31-$2.47M
2021-12-31-$2.03M
2021-03-31-$1.94M
2020-12-31-$1.24M
2020-03-31-$1.13M
2019-12-31-$668,705.00
2019-03-31-$995,972.00
2018-12-31-$519,212.00
2018-03-31-$808,849.00
2017-12-31-$816,021.00
2017-03-31-$311,486.00

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$12.2M
2024-12-31-$6.4M
2023-12-31-$7.86M
2022-12-31-$7.23M
2021-12-31-$7.32M
2020-12-31-$4.66M
2019-12-31-$3.02M
2018-12-31-$2.68M
2017-12-31-$2.63M
2016-12-31-$1.19M